Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2025)

Arcturus Therapeutics Holdings' Operating Income history spans 8 years, with the latest figure at -$31.3 million for Q4 2025.

  • For Q4 2025, Operating Income rose 6.25% year-over-year to -$31.3 million; the TTM value through Dec 2025 reached -$76.3 million, up 20.29%, while the annual FY2025 figure was -$76.3 million, 20.29% up from the prior year.
  • Operating Income reached -$31.3 million in Q4 2025 per ARCT's latest filing, down from -$16.5 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $121.5 million in Q4 2022 to a low of -$57.7 million in Q1 2021.
  • Average Operating Income over 5 years is -$22.0 million, with a median of -$26.3 million recorded in 2022.
  • Peak YoY movement for Operating Income: crashed 509.45% in 2021, then surged 422.62% in 2022.
  • A 5-year view of Operating Income shows it stood at -$37.6 million in 2021, then soared by 422.62% to $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then crashed by 82.76% to -$33.4 million in 2024, then rose by 6.25% to -$31.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Operating Income are -$31.3 million (Q4 2025), -$16.5 million (Q3 2025), and -$11.6 million (Q2 2025).